GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

CHCI · Mar 31, 2021

Comstock Holding Companies, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001299969-21-000012General Corporate
Operating cash generation10thOwn-history percentile · N=10
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-23.12% · OPTIONAL · VALID

Revenue growth63thOwn-history percentile · N=8
Evidence method

Yoy · gp.fundamentals.revenue

19.39% · CORE · VALID

Gross margin80thOwn-history percentile · N=10
Evidence method

Level · gp.fundamentals.gross_margin

13.85% · CORE · VALID

Operating margin58thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.operating_margin

3.61% · CORE · VALID

SBC intensity50thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

2.21% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History35 statesSelf-history eligible
Period transition

What moved in the state?

Cash Generation Decreased
Previous
11.96%
Current
-23.12%
Delta
-35.08%
Growth Increased
Previous
13.47%
Current
19.39%
Delta
5.93%
Profitability Decreased
Previous
8.94%
Current
3.61%
Delta
-5.33%
Sbc Intensity Decreased
Previous
2.70%
Current
2.21%
Delta
-0.49%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.